Key result
[68Ga]pentixafor PET/CT demonstrated significantly higher uptake than [18F]FDG PET/CT in lymphoplasmacytic lymphoma and marginal zone lymphoma, indicating its potential for staging these subtypes.
Why the study?
To evaluate CXCR4 expression using [68Ga]pentixafor PET across various types of non-Hodgkin lymphoma and compare findings with [18F]FDG PET/CT.
Does [68Ga]pentixafor PET/CT improve lesion detection compared to [18F]FDG PET/CT in patients with newly diagnosed non-Hodgkin lymphoma?
Observational (n=27)
No
Does [68Ga]pentixafor PET/CT improve lesion detection compared to [18F]FDG PET/CT in patients with newly diagnosed non-Hodgkin lymphoma?
Absolute Event Rate: 11.6% vs 3.2%
p-value: p=<0.01
[68Ga]pentixafor PET/CT detects CXCR4 overexpression in various non-Hodgkin lymphomas and shows higher uptake than [18F]FDG in lymphoplasmacytic and marginal zone lymphomas.
May inform subtype-specific CXCR4 imaging in NHL; hypothesis-generating and should not yet change FDG-based practice.
Background: In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with [18F]FDG PET/CT. Results: Twenty-seven patients with newly diagnosed non-Hodgkin lymphoma were recruited retrospectively. [68Ga]pentixafor PET showed increased radioactivity in lymphoplasmacytic lymphoma (n = 8), marginal zone lymphoma (n = 4), diffuse large B cell lymphoma (n = 3), follicular lymphoma (n = 2), mantle cell lymphoma (n = 1), unclassified indolent B cell lymphoma (n = 3) and enteropathy associated T cell lymphoma (n = 3). However, peripheral T cell lymphoma, not otherwise specified (n = 1), and NK/T cell lymphoma (n = 2) were not avid for [68Ga]pentixafor. In comparison to [18F]FDG PET, [68Ga]pentixafor PET demonstrated more extensive disease and higher radioactivity in lymphoplasmacytic lymphoma and marginal zone lymphoma. Conclusion: CXCR4 expression varies in different types of non-Hodgkin lymphoma. Overexpression of CXCR4 was detected with [68Ga]pentixafor PET/CT in lymphoplasmacytic lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, unclassified indolent B cell lymphoma, and enteropathy associated T cell lymphoma. The uptake of [68Ga]pentixafor was higher than [18F]FDG in lymphoplasmacytic lymphoma and marginal zone lymphoma.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2020) conducted an observational in non-Hodgkin lymphoma (n=27). [68Ga]pentixafor PET/CT vs. [18F]FDG PET/CT was evaluated on Maximum standard uptake value (SUVmax) in lymphoplasmacytic lymphoma (p=<0.01). [68Ga]pentixafor PET/CT demonstrated significantly higher uptake than [18F]FDG PET/CT in lymphoplasmacytic lymphoma and marginal zone lymphoma, indicating its potential for staging these subtypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: